Recap: DexCom Q3 Earnings

Shares of DexCom DXCM rose 1.15% in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 44.62% over the past year to $0.94, which beat the estimate of $0.64.

Revenue of $500,900,000 up by 26.39% from the same period last year, which beat the estimate of $476,750,000.

Outlook

DexCom hasn't issued any earnings guidance for the time being.

The upcoming fiscal year's revenue expected to be between $1,900,000,000 and $1,900,000,000.

Details Of The Call

Date: Oct 27, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/ctub67qk

Price Action

Company's 52-week high was at $456.23

Company's 52-week low was at $145.23

Price action over last quarter: down 10.66%

Company Description

Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.